S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?

Catalent Stock Price, News & Analysis (NYSE:CTLT)

$37.95
-0.96 (-2.47%)
(As of 12/6/2023 ET)
Compare
Today's Range
$37.94
$39.40
50-Day Range
$32.17
$46.57
52-Week Range
$31.45
$74.49
Volume
1.12 million shs
Average Volume
3.13 million shs
Market Capitalization
$6.84 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.45

Catalent MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
33.0% Upside
$50.45 Price Target
Short Interest
Bearish
5.94% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
1.10mentions of Catalent in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
153.70%
From $0.54 to $1.37 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

139th out of 957 stocks

Pharmaceutical Preparations Industry

33rd out of 399 stocks


CTLT stock logo

About Catalent Stock (NYSE:CTLT)

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.

CTLT Stock Price History

CTLT Stock News Headlines

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Baird Upgrades Catalent (CTLT)
What 9 Analyst Ratings Have To Say About Catalent
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
Catalent Shares Rise After Preliminary Q1 Results Beat Analysts' View
Catalent trades higher after quarterly beat
Recap: Catalent Q1 Earnings
Catalent beats quarterly revenue estimates
Catalent beats on revenue in delayed results
Catalent Q1 2024 Earnings Preview
See More Headlines
Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2023
Today
12/06/2023
Next Earnings (Estimated)
2/06/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
19,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$50.45
High Stock Price Target
$62.00
Low Stock Price Target
$42.00
Potential Upside/Downside
+33.0%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
12 Analysts

Profitability

Net Income
$-232,000,000.00
Pretax Margin
-26.53%

Debt

Sales & Book Value

Annual Sales
$4.28 billion
Cash Flow
$1.37 per share
Book Value
$25.71 per share

Miscellaneous

Free Float
179,226,000
Market Cap
$6.84 billion
Optionable
Optionable
Beta
1.27
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report














CTLT Stock Analysis - Frequently Asked Questions

Should I buy or sell Catalent stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CTLT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTLT, but not buy additional shares or sell existing shares.
View CTLT analyst ratings
or view top-rated stocks.

What is Catalent's stock price target for 2024?

12 Wall Street analysts have issued 1-year target prices for Catalent's shares. Their CTLT share price targets range from $42.00 to $62.00. On average, they expect the company's stock price to reach $50.45 in the next twelve months. This suggests a possible upside of 33.0% from the stock's current price.
View analysts price targets for CTLT
or view top-rated stocks among Wall Street analysts.

How have CTLT shares performed in 2023?

Catalent's stock was trading at $45.01 at the beginning of the year. Since then, CTLT shares have decreased by 15.7% and is now trading at $37.95.
View the best growth stocks for 2023 here
.

Are investors shorting Catalent?

Catalent saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 10,700,000 shares, an increase of 5.9% from the October 31st total of 10,100,000 shares. Based on an average trading volume of 2,440,000 shares, the days-to-cover ratio is presently 4.4 days.
View Catalent's Short Interest
.

When is Catalent's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 6th 2024.
View our CTLT earnings forecast
.

How were Catalent's earnings last quarter?

Catalent, Inc. (NYSE:CTLT) posted its earnings results on Wednesday, November, 15th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.04. The business earned $982 million during the quarter, compared to analyst estimates of $939.62 million. Catalent had a negative net margin of 22.36% and a positive trailing twelve-month return on equity of 1.54%. The company's quarterly revenue was down 3.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.25 earnings per share.
Read the conference call transcript
.

What is John R. Chiminski's approval rating as Catalent's CEO?

391 employees have rated Catalent Chief Executive Officer John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).

Who are Catalent's major shareholders?

Catalent's stock is owned by a number of retail and institutional investors. Top institutional investors include Veritas Asset Management LLP (3.68%), Cadian Capital Management LP (2.94%), Barclays PLC (2.66%), Ameriprise Financial Inc. (1.93%), Invesco Ltd. (1.56%) and Morgan Stanley (1.24%). Insiders that own company stock include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, Charles Lickfold, Gregory T Lucier, John J Greisch, John R Chiminski, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Kay A Schmidt, Manja Boerman, Mario Gargiulo, Michael A Riley, Michael J Grippo, Michelle R Ryan, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Steven L Fasman, Thomas P Castellano, Thomas W Hawkeswood and Wetteny Joseph.
View institutional ownership trends
.

How do I buy shares of Catalent?

Shares of CTLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:CTLT) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -